Literature DB >> 29134313

Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience.

Francesca Torresan1, Elisabetta Cavedon2, Caterina Mian2, Maurizio Iacobone3.   

Abstract

BACKGROUND: Medullary thyroid carcinoma (MTC) is a rare C cells-derived tumor, with a hardly predictable long-term prognosis. This study was aimed to evaluate the predictive factors of cure and survival after surgery for MTC in a monocentric series.
METHODS: A retrospective analysis of the long-term outcomes was assessed in 255 MTC patients operated between 1980 and 2015 at Padua University hospital.
RESULTS: Sporadic MTC occurred in 65.1% and hereditary MTC in 34.9% of patients. At a median follow-up of 93 months (range 7-430), the cure rate was 56.8%. The overall 10-year survival was 84.4%, and MTC-related death rate was 15.3%. Patients who died because of MTC had a median age of 61 years (range 21-84) and were at stages III-IV in all cases; deaths occurred in 18% of sporadic MTC, 6% of MEN2a and 66.7% of MEN2b patients. None of the patients at stages I-II died because of the disease, but 17.7% had persistent/recurrent disease. Based on univariate analysis, age, gender, genetic variant, extent and year of surgery, tumor size, lymph-nodal metastases and tumor stage significantly affected cure and survival rates. At multivariate analysis, only patient- and tumor-related features (age, lymph-nodal status and stage) remained significant independent prognostic factors.
CONCLUSIONS: Radical surgery is the only chance of definitive cure in MTC, but it is possible only at early stage; in advanced stages, even extensive surgery could not grant cure and prolonged survival. Stage, nodal metastases and age remain the main predictive factors for cure and survival.

Entities:  

Mesh:

Year:  2018        PMID: 29134313     DOI: 10.1007/s00268-017-4321-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  32 in total

1.  Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.

Authors:  Cristina Romei; Clara Ugolini; Barbara Cosci; Liborio Torregrossa; Agnese Vivaldi; Raffaele Ciampi; Alessia Tacito; Fulvio Basolo; Gabriele Materazzi; Paolo Miccoli; Paolo Vitti; Aldo Pinchera; Rossella Elisei
Journal:  Thyroid       Date:  2012-03-09       Impact factor: 6.568

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 3.  Medullary thyroid carcinoma.

Authors:  F Pacini; M G Castagna; C Cipri; M Schlumberger
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-08       Impact factor: 4.126

4.  Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

Authors:  Sanziana Roman; Rong Lin; Julie Ann Sosa
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

5.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

Authors:  Andreas Machens; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2010-03-25       Impact factor: 5.958

6.  Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register.

Authors:  F Raue; J Kotzerke; D Reinwein; S Schröder; H D Röher; H Deckart; R Höfer; M Ritter; F Seif; H Buhr
Journal:  Clin Investig       Date:  1993-01

7.  Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system.

Authors:  Andreas Machens; Henning Dralle
Journal:  Ann Surg       Date:  2013-02       Impact factor: 12.969

8.  Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.

Authors:  Päivi Siironen; Jaana Hagström; Hanna O Mäenpää; Johanna Louhimo; Johanna Arola; Caj Haglund
Journal:  Acta Oncol       Date:  2015-09-04       Impact factor: 4.089

9.  Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.

Authors:  Maria R Pelizzo; Francesca Torresan; Isabella M Boschin; Davide Nacamulli; Gianmaria Pennelli; Susi Barollo; Domenico Rubello; Caterina Mian
Journal:  Am J Clin Oncol       Date:  2015-10       Impact factor: 2.339

10.  Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.

Authors:  M E Dottorini; A Assi; M Sironi; G Sangalli; G Spreafico; L Colombo
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

View more
  10 in total

1.  Surgical selection and prognostic analysis in patients with unilateral sporadic medullary thyroid carcinoma.

Authors:  Jinming Zhang; Pengfei Gu; Dongmei Huang; Jingzhu Zhao; Xiangqian Zheng; Ming Gao
Journal:  Langenbecks Arch Surg       Date:  2022-06-24       Impact factor: 3.445

2.  Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Updates Surg       Date:  2022-07-12

Review 3.  Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Authors:  Antonio Matrone; Carla Gambale; Alessandro Prete; Rossella Elisei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 6.055

4.  68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers.

Authors:  Pedro Souteiro; Patrícia Gouveia; Gonçalo Ferreira; Sandra Belo; Cláudia Costa; Davide Carvalho; Hugo Duarte; Inês Lucena Sampaio
Journal:  Endocrine       Date:  2019-01-25       Impact factor: 3.633

5.  The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway.

Authors:  Else Marie Opsahl; Lars Andreas Akslen; Ellen Schlichting; Turid Aas; Katrin Brauckhoff; Anne Irene Hagen; Alf Frimann Rosenlund; Eva Sigstad; Krystyna K Grøholt; Lars H Jørgensen; Trine Bjøro
Journal:  Eur Thyroid J       Date:  2019-04-29

Review 6.  Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.

Authors:  Carrie C Lubitz; Peter M Sadow; Gilbert H Daniels; Lori J Wirth
Journal:  Thyroid       Date:  2021-06-22       Impact factor: 6.506

7.  A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.

Authors:  Keisuke Enomoto; Fuyuki Sato; Shunji Tamagawa; Mehmet Gunduz; Naoyoshi Onoda; Shinya Uchino; Yasuteru Muragaki; Muneki Hotomi
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

8.  Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection.

Authors:  Qin Huang; Aihua Hu; Mingsheng Zhang
Journal:  BMC Endocr Disord       Date:  2020-05-14       Impact factor: 2.763

9.  Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

10.  Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study.

Authors:  Else Marie Opsahl; Lars Andreas Akslen; Ellen Schlichting; Turid Aas; Katrin Brauckhoff; Anne Irene Hagen; Alf Frimann Rosenlund; Eva Sigstad; Krystyna K Grøholt; Lovise Mæhle; Lars Fredrik Engebretsen; Lars H Jørgensen; Jan Erik Varhaug; Trine Bjøro
Journal:  Eur Thyroid J       Date:  2018-11-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.